Polaryx Therapeutics, Inc.
PLYX
$3.37
$0.092.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -5.90% | 10.31% | 25.54% | -21.31% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 26.00% | 26.33% | -29.39% | 214.57% | |
| Operating Income | -26.00% | -26.33% | 29.39% | -214.57% | |
| Income Before Tax | -106.78% | -85.47% | 19.49% | 81.70% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -106.78% | -85.47% | 19.49% | 81.70% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -106.78% | -85.47% | 19.49% | 81.70% | |
| EBIT | -26.00% | -26.33% | 29.39% | -214.57% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -73.37% | -53.69% | 36.87% | 89.89% | |
| Normalized Basic EPS | -73.04% | -53.54% | 37.05% | 89.89% | |
| EPS Diluted | -73.37% | -53.69% | 36.87% | 89.89% | |
| Normalized Diluted EPS | -73.04% | -53.54% | 37.05% | 89.89% | |
| Average Basic Shares Outstanding | 19.39% | 20.48% | 27.89% | 80.92% | |
| Average Diluted Shares Outstanding | 19.39% | 20.48% | 27.89% | 80.92% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |